Senolytics Reduce Harmful Microglia in Aging Mouse Brains

**Researchers identified a population of inflammatory and senescent microglia concentrated in the white matter of aged mice. Several senolytic therapies reduced these cells and partially restored the fimbria to a more youthful organization, although clinical evidence in humans is still very limited.

• The study detected microglia with senescence traits and disease-associated microglia in the fimbria, a region of white matter near the hippocampus.
• The genetic signature SenBrain includes the expression of galectin-3, also identified as GAL3 or Lgals3.
• Pharmacogenetic and pharmacological interventions reduced GAL3+ microglia and partially restored a more youthful microglial organization in mice.

A team of researchers identified a population of microglia in aged mice that combines senescence traits with disease-associated characteristics. These cells are particularly concentrated in the white matter near the hippocampus, especially in the fimbria, and their presence is associated with a more inflammatory brain environment that is vulnerable to age-related deterioration.

The work evaluated several senolytic approaches, which are strategies designed to eliminate senescent cells or reduce their harmful accumulation. According to the report from Fight Aging!, the interventions decreased the abundance of disease-associated GAL3+ microglia and helped partially recover a microglial organization more similar to that observed in young animals, although the results still correspond to mouse models.

A Cell Population Concentrated in White Matter

The brain's white matter undergoes structural and functional changes during aging, and these alterations have been linked to cognitive decline. However, the cellular and molecular explanation for its selective vulnerability is not yet fully defined, which is why the study focuses on an area that has long received less attention than other brain regions.

Microglia are part of the brain's innate immune system and perform functions of surveillance, maintenance, and response to damage. Over time, some of these cells may adopt persistent states of activation and inflammation, a transformation that ceases to be protective when it continuously affects the neuronal environment and the structure of brain circuits.

In aged mice, researchers found that disease-associated microglia phenotypes, known as DAM, converge with a senescence signature within the white matter adjacent to the hippocampus. The fimbria stood out as a point of accumulation, suggesting that certain brain connection pathways may be particularly sensitive to the combination of aging, inflammation, and cellular changes.

The finding does not imply that all microglia present in an old brain are harmful or that senescence alone explains cognitive decline. Rather, it identifies a specific and enriched cellular state in a particular region, whose presence seems prominent and, at least in part, susceptible to modification through targeted interventions.

How They Identified Senescent Cells

To characterize this population, the team combined regional gene expression profiles with GeoMx immunostaining techniques, digital spatial profiling, and CosMx spatial molecular imaging. The combined use of these tools allowed researchers to observe not only which genes the cells expressed but also where they were located within the aged brain tissue and with which other cellular states they shared space.

The analyses revealed a microglial population exclusive to the aging brain and concentrated in the white matter. Its cells expressed genes linked to the DAM phenotype along with a senescence signature termed SenBrain, which includes galectin-3, identified in the data as GAL3 or Lgals3.

Galectin-3 acted as a relevant signal to distinguish the microglial population that accumulated inflammatory and senescent traits. The presence of GAL3+ cells in the white matter provided researchers with a marker to track the effect of therapies and compare the organization of aging tissue with a state considered more youthful.

Moreover, spatial trajectory analyses of individual cells suggested that the observed state does not necessarily arise through a single pathway. Multiple cellular fate transitions could lead to aged, pro-inflammatory microglia associated simultaneously with senescence and disease, a conclusion that underscores the complexity of designing treatments targeting this population.

The Effect of Senotherapeutic Interventions

Researchers tested two types of senotherapeutic interventions: pharmacogenetic and pharmacological. In both cases, the goal was to reduce the presence of disease-associated GAL3+ microglia within the white matter, rather than indiscriminately modifying all immune cells in the brain.

The interventions reduced the abundance of that cellular population and partially restored a more youthful microglial organization in the aging fimbria. The result supports the idea that part of the disorganization associated with aging is not completely fixed, although the experiment does not allow concluding that the same effect will appear with equal intensity in humans.

The study published in Nature Aging suggests that the elimination of senescent cells could benefit the white matter by decreasing an inflammatory component that disrupts its functioning. This interpretation aligns with previous work in mouse models, where the removal of senescent cells has been linked to improvements in cognitive function and favorable changes in neurodegeneration processes.

The relevance of the result also lies in the convergence of methods and treatments: first, the harmful population was located using spatial tools, and then its reduction was observed following the interventions. Nevertheless, the effect should be understood as an experimental demonstration in animals, not as evidence that a proven senolytic can prevent or treat neurodegenerative diseases in patients.

The Gap Between Mice and Patients

Senolytics have garnered interest because they aim to target a characteristic of cellular aging, rather than merely alleviating its consequences. In the brain, this strategy faces an additional challenge: any treatment must reach the appropriate regions and preserve the functions of healthy microglia, which remain necessary for immune surveillance and tissue maintenance.

The clinical evaluation of senolytic drugs for neurodegenerative conditions is still limited. There are studies evaluating combinations such as dasatinib and quercetin in the context of Alzheimer’s disease, but the available clinical evidence remains very sparse compared to the volume of results obtained in animal models.

Therefore, the discovery of senescent microglia in the fimbria should not be presented as a cure for brain aging. Its importance lies in providing a more defined cellular and spatial target, as well as offering a way to measure whether a therapy can change the environment of the white matter without causing damage to other regions of the nervous system.

The next step will be to determine whether the SenBrain signature, galectin-3, and the DAM state also appear in aging human brains and to what extent they relate to clinical symptoms. While those answers are not yet available, the results suggest a promising but still experimental possibility: reducing a fraction of the harmful microglia could help restore functions of the aging brain, although medical translation requires further studies on safety and efficacy.

This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.